NASDAQ:IMGN
ImmunoGen Stock News
$31.23
+0 (+0%)
At Close: May 08, 2024
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results
04:01pm, Thursday, 20'th Oct 2022
WALTHAM, Mass.
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference
04:30pm, Wednesday, 14'th Sep 2022
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
02:40pm, Friday, 09'th Sep 2022 Benzinga
Upgrades
For 3M Co (NYSE:MMM), UBS upgraded the previous rating of Sell to Neutral. For the second quarter, 3M had an EPS of $2.48, compared to year-ago quarter EPS of $2.59. The current stock perform
Why Is Pacira (PCRX) Down 9.2% Since Last Earnings Report?
03:31pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate
04:42pm, Thursday, 01'st Sep 2022 Zacks Investment Research
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue?
03:31pm, Thursday, 01'st Sep 2022 Zacks Investment Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate
01:53pm, Thursday, 01'st Sep 2022
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
03:13pm, Monday, 01'st Aug 2022 Zacks Investment Research
ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
12:24pm, Monday, 01'st Aug 2022
ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.
ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript
03:30pm, Saturday, 30'th Jul 2022 The Motley Fool
IMGN earnings call for the period ending June 30, 2022.
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q2 2022 Results - Earnings Call Transcript
11:45am, Friday, 29'th Jul 2022
ImmunoGen, Inc. (NASDAQ:IMGN ) Q2 2022 Results Conference Call July 29, 2022 8:00 AM ET Company Participants Anabel Chan - Head of Investor Relations Mark Enyedy - President, CEO Anna Berkenblit - CMO
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates
11:45am, Friday, 29'th Jul 2022 Zacks Investment Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of -9.09% and 16.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates
09:21am, Friday, 29'th Jul 2022
ImmunoGen (IMGN) delivered earnings and revenue surprises of -9.09% and 16.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen: Possible Accelerated FDA Approval For Ovarian Cancer Treatment
02:51pm, Monday, 20'th Jun 2022
PDUFA date with Priority Review for mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha set for November 28, 2022. Confirmatory MIRASOL study trial readout of mirvetu
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
02:02pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.
